## Edgar Filing: ACORDA THERAPEUTICS INC - Form 4

ACORDA T Form 4 October 07,	THERAPEUTICS	INC									
	ЛЛ								OMB AF	PROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287		
Subject to Section 16. Form 4 or				NGES IN BENEFICIAL OWNERSHIP O SECURITIES 16(a) of the Securities Exchange Act of 1934					Expires: January 20 Estimated average burden hours per response		
obligatic may con <i>See</i> Instr 1(b).	tinue. Section 17	a) of the l	Public U	tility Hol	lding Co	mpar	•	1935 or Section	I		
(Print or Type	Responses)										
1. Name and A Wasman Ja	Address of Reporting ne	Person <u>*</u>	Symbol	er Name <b>an</b> DA THE			8	5. Relationship of I Issuer (Check	Reporting Pers		
(Last) 420 SAW M	(First) (	Middle) AD		of Earliest T Day/Year) 2014	ransaction	l		Director X Officer (give below) Preside			
				Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
ARDSLEY	, NY 10502							Form filed by M Person			
(City)	(State)	(Zip)	Tab	le I - Non-J	Derivative	e Secu	rities Acqu	iired, Disposed of,	or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	4. Securi oror Dispo (Instr. 3,	sed of		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	10/03/2014			Code V S	Amount 3,750 (1)	(D) D	Price \$ 34.1288 (2)		D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Instr. 8	5. tionNumber of ) Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	3	Date	Amou Unde Secur	le and ant of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
				Code Y		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## Edgar Filing: ACORDA THERAPEUTICS INC - Form 4

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships							
	Director	10% Owner	Officer	Other				
Wasman Jane 420 SAW MILL RIVER ROAD ARDSLEY, NY 10502			President, Intl and GC					
Signatures								
/s/ Jane Wasman 10/0	7/2014							

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from \$33.85 to (2) \$34.35 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.